Loading...

We've got a brand new version of Simply Wall St! Try it out

RISE Life Science

CNSX:RLSC
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RLSC
CNSX
CA$4M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

RISE Life Science Corp. engages in developing and evolving medical and adult hemp-based formulations to create general use health and well-being products for the consumer category in the United States. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • RISE Life Science has significant price volatility in the past 3 months.
RLSC Share Price and Events
7 Day Returns
-25%
CNSX:RLSC
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-72.1%
CNSX:RLSC
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
RLSC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
RISE Life Science (RLSC) -25% -47.8% -70% -72.1% -80.3% -99%
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • RLSC underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • RLSC underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
RLSC
Industry
5yr Volatility vs Market

RLSC Value

 Is RISE Life Science undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether RISE Life Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as RISE Life Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for RISE Life Science. This is due to cash flow or dividend data being unavailable. The share price is CA$0.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for RISE Life Science's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are RISE Life Science's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:RLSC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in CAD CA$-0.23
CNSX:RLSC Share Price ** CNSX (2019-09-20) in CAD CA$0.06
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of RISE Life Science.

CNSX:RLSC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:RLSC Share Price ÷ EPS (both in CAD)

= 0.06 ÷ -0.23

-0.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RISE Life Science is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • RISE Life Science is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does RISE Life Science's expected growth come at a high price?
Raw Data
CNSX:RLSC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for RISE Life Science, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on RISE Life Science's assets?
Raw Data
CNSX:RLSC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in CAD CA$-0.11
CNSX:RLSC Share Price * CNSX (2019-09-20) in CAD CA$0.06
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:RLSC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:RLSC Share Price ÷ Book Value per Share (both in CAD)

= 0.06 ÷ -0.11

-0.55x

* Primary Listing of RISE Life Science.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RISE Life Science has negative assets, we can't compare the value of its assets to the CA Pharmaceuticals industry average.

Next steps:

  1. Take a look at our analysis of RLSC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through RISE Life Science's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess RISE Life Science's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. RISE Life Science has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RLSC Future Performance

 How is RISE Life Science expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RISE Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is RISE Life Science expected to grow at an attractive rate?
  • Unable to compare RISE Life Science's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare RISE Life Science's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare RISE Life Science's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:RLSC Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:RLSC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:RLSC Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-05-31 1 -8 -14
2019-02-28 0 -5 -13
2018-11-30 0 -4 -12
2018-08-31 0 -4 -5
2018-05-31 -3 -3
2018-02-28 -2 -2
2017-11-30 -2 -2
2017-08-31 -1 -2
2017-05-31 -1 -2
2017-02-28 -1 -1
2016-11-30 0 -1
2016-08-31 0 0 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if RISE Life Science is high growth as no earnings estimate data is available.
  • Unable to determine if RISE Life Science is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:RLSC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from RISE Life Science Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:RLSC Past Financials Data
Date (Data in CAD Millions) EPS *
2019-05-31 -0.23
2019-02-28 -0.24
2018-11-30 -0.24
2018-08-31 -0.16
2018-05-31 -0.10
2018-02-28 -0.11
2017-11-30 -0.18
2017-08-31 -0.24
2017-05-31 -0.30
2017-02-28 -0.40
2016-11-30 -0.50
2016-08-31 -1.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if RISE Life Science will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of RLSC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. RISE Life Science's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. RISE Life Science's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess RISE Life Science's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
RISE Life Science has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RLSC Past Performance

  How has RISE Life Science performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare RISE Life Science's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • RISE Life Science does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare RISE Life Science's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare RISE Life Science's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
RISE Life Science's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from RISE Life Science Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:RLSC Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 0.89 -13.64 7.00
2019-02-28 0.29 -13.18 6.52
2018-11-30 0.19 -11.86 5.43
2018-08-31 0.14 -5.13 4.81
2018-05-31 -3.13 2.71
2018-02-28 -2.28 1.88
2017-11-30 -2.39 1.99
2017-08-31 -1.74 1.22
2017-05-31 -1.66 1.14
2017-02-28 -1.47 0.94
2016-11-30 -1.11 0.58
2016-08-31 0.00 -2.03 0.59
2016-05-31 0.00 -2.49 1.02
2016-02-29 0.00 -2.88 1.41
2015-11-30 0.01 -3.29 1.80
2015-08-31 0.01 -2.58 2.23
2015-05-31 0.02 -2.69 2.26
2015-02-28 0.02 -2.56 2.35
2014-11-30 0.01 -1.91 2.41
2014-08-31 0.03 -2.36 2.50
2014-05-31 0.03 -2.58 2.81
2014-02-28 0.02 -2.84 2.85
2013-11-30 0.09 -3.50 2.80
2013-08-31 0.09 -3.19 2.57
2013-05-31 0.12 -2.84 2.08
2013-02-28 0.16 -2.81 2.01
2012-11-30 0.13 -2.70 1.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if RISE Life Science has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if RISE Life Science has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if RISE Life Science improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess RISE Life Science's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
RISE Life Science has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RLSC Health

 How is RISE Life Science's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up RISE Life Science's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • RISE Life Science is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • RISE Life Science's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of RISE Life Science's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • RISE Life Science has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from RISE Life Science Company Filings, last reported 3 months ago.

CNSX:RLSC Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 -6.50 8.63 1.58
2019-02-28 -5.03 6.48 2.97
2018-11-30 -3.49 5.12 3.88
2018-08-31 3.15 1.69 0.83
2018-05-31 2.74 1.66 0.82
2018-02-28 1.85 1.66 0.43
2017-11-30 -0.70 1.76 1.07
2017-08-31 -3.36 1.76 0.14
2017-05-31 -3.13 1.76 0.13
2017-02-28 -2.72 1.75 0.34
2016-11-30 -3.48 1.77 0.13
2016-08-31 -3.38 1.92 0.01
2016-05-31 -3.18 1.87 0.01
2016-02-29 -2.95 1.87 0.05
2015-11-30 -2.71 1.60 0.00
2015-08-31 -1.47 1.56 0.01
2015-05-31 -1.16 1.52 0.02
2015-02-28 -0.98 1.48 0.01
2014-11-30 -0.72 1.54 1.16
2014-08-31 -1.31 1.50 0.09
2014-05-31 -1.19 1.48 0.03
2014-02-28 -1.09 1.34 0.03
2013-11-30 -1.23 0.98 0.16
2013-08-31 -1.07 0.97 0.03
2013-05-31 -0.21 0.95 0.63
2013-02-28 -0.44 0.94 0.37
2012-11-30 0.16 0.93 0.91
  • RISE Life Science has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if RISE Life Science's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • RISE Life Science has less than a year of cash runway based on current free cash flow.
  • RISE Life Science has less than a year of cash runway if free cash flow continues to grow at historical rates of 84.5% each year.
X
Financial health checks
We assess RISE Life Science's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. RISE Life Science has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RLSC Dividends

 What is RISE Life Science's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from RISE Life Science dividends.
If you bought CA$2,000 of RISE Life Science shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate RISE Life Science's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate RISE Life Science's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:RLSC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as RISE Life Science has not reported any payouts.
  • Unable to verify if RISE Life Science's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of RISE Life Science's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as RISE Life Science has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess RISE Life Science's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can RISE Life Science afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. RISE Life Science has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RLSC Management

 What is the CEO of RISE Life Science's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Scott Secord
COMPENSATION CA$685,240
TENURE AS CEO 0.4 years
CEO Bio

Mr. Scott Lawrence Secord has been an Executive Chairman of RISE Life Science Corp. since October 2, 2018 and as its Interim Chief Executive Officer since April 30, 2019. He served as the Chief Executive Officer of Gaming Nation Inc. since June 2015 and its President. He was Chief Executive Officer of Pointstreak Sports Technologies Inc from 2009 to 2015 and its President. During his tenure, the company achieved rapid revenue growth earning awards that included Deloitte's Technology Fast 50 Winner in 2012 as one of the fifty fastest growing technology companies in Canada and Deloitte's Technology Fast 500 Winner in 2014 as one of the 500 fastest growing technology companies in North America. While serving in this position, Pointstreak made five acquisitions, including the acquisition of 5050 Central Ltd., which was subsequently sold to Gaming Nation. 5050 Central was a finalist in 2013 for the Sports Business Journal award for "Best New Technology in Sport". Mr. Secord orchestrated the sale of the remaining core assets of Pointstreak in a transaction with Providence Equities and Blue Star Sports in 2016. Mr. Secord has been Director at Gaming Nation Inc. since July 9, 2015 and DMi, Inc. He served as a Director at Oceanside Capital Corp. since June 2015.

CEO Compensation
  • Insufficient data for Scott to compare compensation growth.
  • Scott's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the RISE Life Science management team in years:

0.9
Average Tenure
  • The average tenure for the RISE Life Science management team is less than 2 years, this suggests a new team.
Management Team

Scott Secord

TITLE
Executive Chairman & Interim CEO
COMPENSATION
CA$685K
TENURE
0.4 yrs

Robert Lelovic

TITLE
Chief Financial Officer
COMPENSATION
CA$245K
TENURE
1.6 yrs

Anton Mattadeen

TITLE
Consultant
COMPENSATION
CA$256K
TENURE
0.9 yrs

Chris Dollard

TITLE
Consultant
COMPENSATION
CA$275K
TENURE
0.9 yrs

Mike Kish

TITLE
Vice President of Sales

Andy DangVu

TITLE
Chief Product Specialist

Chris Moreau

TITLE
Consultant
COMPENSATION
CA$51K
TENURE
3.4 yrs

John Maynard

TITLE
Consultant of Scout DS Technology

James Overbeck

TITLE
Engineering Consultant

Sandra Benson

TITLE
Manager of Investor Relations
Board of Directors Tenure

Average tenure of the RISE Life Science board of directors in years:

3
Average Tenure
  • The average tenure for the RISE Life Science board of directors is less than 3 years, this suggests a new board.
Board of Directors

Scott Secord

TITLE
Executive Chairman & Interim CEO
COMPENSATION
CA$685K
TENURE
0.9 yrs

Edward Hillhouse

TITLE
Chairman of Medical Scientific Advisory Board
TENURE
2.3 yrs

Isabella Caniggia

TITLE
Member of Scientific Advisory Board
TENURE
10.6 yrs

G.B. Mancini

TITLE
Member of The Prevu Medical Advisory Board

Henry Solomon

TITLE
Member of Prevu Medical Advisory Board
TENURE
7.6 yrs

Milan Gupta

TITLE
Member of Prevu Medical Advisory Board

Alain Sotto

TITLE
Member of The Scout DS(R) Medical Advisory Board
TENURE
4.5 yrs

Ashwath Mehra

TITLE
Director
COMPENSATION
CA$131K
AGE
54
TENURE
3.6 yrs

Michael Campbell

TITLE
Director
COMPENSATION
CA$220K
TENURE
1.6 yrs

Greg Mills

TITLE
Director
AGE
57
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
07. Feb 19 Buy Scott Secord Individual 05. Feb 19 07. Feb 19 45,000 CA$0.29 CA$12,757
01. Feb 19 Buy Scott Secord Individual 01. Feb 19 01. Feb 19 10,000 CA$0.25 CA$2,500
29. Jan 19 Buy Scott Secord Individual 28. Jan 19 28. Jan 19 79,000 CA$0.21 CA$16,195
14. Dec 18 Buy Scott Secord Individual 11. Dec 18 13. Dec 18 42,500 CA$0.16 CA$6,315
11. Dec 18 Buy Scott Secord Individual 10. Dec 18 10. Dec 18 50,000 CA$0.15 CA$7,250
X
Management checks
We assess RISE Life Science's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. RISE Life Science has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RLSC News

Simply Wall St News

RISE Life Science Corp (CNSX:RLSC): Time For A Financial Health Check

While small-cap stocks, such as RISE Life Science Corp (CNSX:RLSC) with its market cap of CA$19.64m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

RLSC Company Info

Description

RISE Life Science Corp. engages in developing and evolving medical and adult hemp-based formulations to create general use health and well-being products for the consumer category in the United States. It also owns its Scout DS device, which is a clinical tool to assist in the identification of prediabetes and type 2 diabetes. The company was formerly known as Luminor Medical Technologies Inc. and changed its name to RISE Life Science Corp. in March 2018. The company is based in Toronto, Canada.

Details
Name: RISE Life Science Corp.
RLSC
Exchange: CNSX
Founded:
CA$3,618,201
60,303,352
Website: http://riselifescience.com
Address: RISE Life Science Corp.
145 King Street West,
Suite 210,
Toronto,
Ontario, M5H IJ8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX RLSC Common Shares Canadian National Stock Exchange CA CAD 25. Sep 2002
OTCPK MCUI.F Common Shares Pink Sheets LLC US USD 25. Sep 2002
DB L02 Common Shares Deutsche Boerse AG DE EUR 25. Sep 2002
Number of employees
Current staff
Staff numbers
0
RISE Life Science employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:45
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/30
Last earnings reported: 2019/05/31
Last annual earnings reported: 2018/11/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.